摘要
目的探讨血清肿瘤标记物糖类抗原125(CA125)、环氧化酶-1(COX-1)联合彩色多普勒超声(经阴道超声、经腹部超声)诊断卵巢癌的临床应用价值。方法选取卵巢恶性肿瘤97例(卵巢癌组)、卵巢良性肿瘤101例(卵巢良性肿瘤纽)为研究对象,均经术后病理或穿刺活检证实,全部有血清肿瘤标记物、彩色多普勒超声(经阴道超声、经腹部超声)检查资料,将各项检查资料与病理对照进行回顾性统计,分析各项检查的优、缺点。结果CA125诊断卵巢癌的敏感性为75.3%(73/97),特异性为92.1%(93/101),准确性为83.8%(166/198);COX-1敏感性为48.5%(47/97),特异性为93.1%(94/101),准确性为71.2%(141/198);经阴道超声敏感性为86.6%(84/97),特异性为94.1%(95/101),准确性为90.4%(179/198);经腹部超声敏感性为82.5%(80/97),特异性为91.1%(92/101),准确性为86.9%(172/198);联合检查的敏感性为96.9%(94/97),特异性为89.1%(90/101),准确性为92.9%(184/198)。结论联合检查可显著提高卵巢癌诊断的敏感性,减少漏诊率,具有重要的临床应用价值.
Objective To investigate the clinical value of serum tumor makers CA125, COX-1 combined with the color Doppler ultrasound in diagnosis of ovarian cancer. Methods Collected materials of 97 patients with malignant tumor of 0vary( ovarian cancer group) and 101 patients with benign ovarian cancer( contrast group). All of them were detected by the postoperative pathology or puncture biopsy to get the data of the serum tumor maker CA125 and the color Doppler ultrasound. Compared with retrospective pathology to analyze the advantages and disadvantages of the detections. Results The sensitivity of CA125 was 75.3% (73/97), specificity 92. 1% (93/101), accuracy 83.8% (166/198) ;The sensitivity of COX-1 was 48.5% (47/97), specificity 93.1% (94/101), accuracy 71.2% (141/198) ; The sensitivity of transvaginal ultrasound was 86.6% (84/97), specificity 94. 1% (95/101), accuracy 90. 4% ( 179/198 ) ; The sensitivity of abdominal ultrasound was 82.5% ( 80/97 ), specificity 91.1% (92/101), accuracy 86.9% (172/198) ; The sensitivity of the combined detections was 96.9% (94/ 97), specificity 89. 1% (90/101), accuracy 92.9% (184/198). Conclusions Combined diagnosis is an effective way to improve the sensitivity of the ovarian cancer with reliable guidance significance.
出处
《中国实用医刊》
2013年第6期26-28,共3页
Chinese Journal of Practical Medicine
关键词
卵巢癌
血清肿瘤标记物
彩色多普勒超声
联合检查
Ovarian cancer
Serum tumor makers
Color Doppler ultrasound
Combined diag-nosis